The CooperCOO +0.35%89 ROC (Joel Greenblatt) % is -3.53% as of Apr. 2026. GuruFocus rates COO with a GF Score™ of 89/100 and a GF Value™ of $100.97 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 840 Medical Devices & Instruments companies, The Cooper ranks better than 65.12% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. The Cooper's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was -3.53%.
The historical rank and industry rank for The Cooper's ROC (Joel Greenblatt) % or its related term are showing as below:
COO'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 15.97 Med: 25.45 Max: 34.64
Current: 16.55
During the past 13 years, The Cooper's highest ROC (Joel Greenblatt) % was 34.64%. The lowest was 15.97%. And the median was 25.45%.
COO's ROC (Joel Greenblatt) % is ranked better than 65.12% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 4.035
vs COO: 16.55
The Cooper's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 6.40% per year.
The Cooper (NAS:COO) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
The Cooper ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for The Cooper's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COO vs SOLV, ALGN, BAX: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, The Cooper's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where The Cooper's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -3.53% mean?
The Cooper (COO) has a ROC (Joel Greenblatt) % of -3.53% as of Apr. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on The Cooper and its competitors. Over the past decade, The Cooper's ROC (Joel Greenblatt) % has ranged from 15.97 to 34.64. According to the industry distribution chart, The Cooper ranks #293 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 34.9%.
Is The Cooper's ROC (Joel Greenblatt) % too high?
The Cooper's current ROC (Joel Greenblatt) % is -3.53%. Over the past 10 years, this metric has ranged from a low of 15.97 to a high of 34.64. Based on the distribution chart, The Cooper ranks #293 out of 840 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, The Cooper has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's ROC (Joel Greenblatt) % compare to SOLV and ALGN?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #293 out of 840 companies for ROC (Joel Greenblatt) %. This puts The Cooper in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 4.04. Historically, The Cooper's own ROC (Joel Greenblatt) % has ranged from 15.97 to 34.64 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.04, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current ROC (Joel Greenblatt) % is -3.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Modestly Undervalued. The stock's GF Value™ is $100.97, compared to a current price of $71.95 — trading 28.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is -3.53%. The Cooper's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For The Cooper (COO), the current ROC (Joel Greenblatt) % is -3.53% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $71.95 is trading 28.7% below its estimated GF Value™ of $100.97.
GuruFocus considers The Cooper to be Modestly Undervalued.
Key valuation signals for COO:
ROC (Joel Greenblatt) %: -3.53%
GF Value™: $100.97 vs. price of $71.95 (28.7% below fair value)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
89GF Score
Get the complete analysis for COO
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
